siRNA Druggable Genome Libraries Now on the Market

Sigma-Aldrich (St. Louis, MO, USA) and Rosetta Inpharmatics (Seattle, WA, USA) have announced the release of two silent RNA (siRNA) druggable genome libraries for human and rat as components of Sigma-Aldrich's Mission product line.

The discovery of RNA interference (siRNA) has been cited as one of the transforming events in biology in the past decade. siRNA can result in gene silencing or even in the expulsion of sequences from the genome. Harnessed as an experimental tool, it has revolutionized approaches to decoding gene function. It also has the potential to be exploited therapeutically, and clinical trials to test this possibility are already being planned.

The Rosetta-powered siRNA design algorithm used by Sigma-Aldrich has been optimized with over three years of continuous development for enhanced performance in interference RNA applications. New and critical rules incorporated into the latest design algorithm lead to increased target specificity and knockdown for low abundance messages.

Mission siRNA druggable genome libraries have been sub-divided into 17 gene family panels using the most up-to-date gene information available, offering siRNA collections unique to the market with this level of gene-family classification. The druggable genome libraries are available for sale in their entirety, or may be purchased by individual gene-family panels.

"Mission siRNA Druggable Genome Libraries offer the most compelling siRNA collections available today by targeting genes of high therapeutic value as defined with input from major pharmaceutical companies,” said Dr. David Smoller, vice president of research and development at Sigma-Aldrich. "The flexible format of Mission siRNA libraries facilitate[s] research for life scientists who are interested in specific classes of genes as well as those who need to generate information across the entire druggable genome.”


Related Links:
Sigma-Aldrich
Rosetta Inpharmatics